Seminars in Oncology
Volume 31, Issue 5 , Pages 605-617, October 2004

Proton magnetic resonance spectroscopic evaluation of brain tumor metabolism

  • Tracy Richmond McKnight

      Affiliations

    • Department of Radiology, University of California, San Francisco, CA, USA.
    • Corresponding Author InformationAddress reprint requests to Tracy Richmond McKnight, PhD, Center for Molecular and Functional Imaging, 185 Berry St, Ste 350, Department of Radiology, University of California, San Francisco, CA 94107.

Magnetic resonance imaging (MRI) is the neuroimaging method of choice for the noninvasive monitoring of patients with brain tumors due to the enormous amount of information it yields regarding the morphologic features of the lesion and surrounding parenchyma. Over the past decade, proton magnetic resonance spectroscopy (1H-MRS), which uses the same technology as MRI and can be performed during a routine clinical imaging examination, has been used to glean information about the metabolic status of the brain. Accurate interpretation of 1H-MRS data from individual patients requires an understanding of the various techniques for acquiring the data, the physiologic basis of the metabolic signatures obtained from different types of tumors, and the specificity of the technique. This review covers the basic physics of 1H-MRS, the spectral and physiological characteristics of the metabolites that are typically measured in various types of brain tumors, and the clinical utility of 1H-MRS with respect to diagnosis, therapeutic planning, and the assessment of response to treatment.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by NCI K01 CA90244 and NCI P50 CA97297.

PII: S0093-7754(04)00325-2

doi:10.1053/j.seminoncol.2004.07.003

Seminars in Oncology
Volume 31, Issue 5 , Pages 605-617, October 2004